莱普作为心血管事件和高血小板反应率的预测因子在接受皮肤冠状动脉干预的患者中
Elisabetta Ricottini1, Laura Gatto2, Annunziata Nusca1
1Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Clinical nutrition ESPEN
|December 6, 2023
概括
高丁水平与经过皮肤冠状动脉干预 (PCI) 的患者心血管结果的恶化有关. 这项研究还发现,升高的勒和高血小板反应率 (HPR) 之间存在关联,这表明PCI后患者之间存在复杂的关系.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 血栓形成的原因之一是血栓形成.
背景情况:
- 建议调节食物摄入量的激素 - - 丁,可以影响血小板聚合和心血管结果.
- 然而,在接受皮肤冠状动脉干预 (PCI) 的患者中,丁,血小板反应性和临床结果之间的体内关系仍未得到充分研究.
研究的目的:
- 研究PCI治疗患者的瘦素水平,血小板活性 (PR) 和长期心血管结果之间的关联.
- 探讨丁水平与不同PR群体 (低,正常,高) 之间的关系.
主要方法:
- 155名接受PCI的患者进行了PR (VerifyNowP2Y12测定) 和莱普血水平 (ELISA) 的程序前测量.
- 超素血症被定义为瘦素水平≥14 ng/ml. 患者被分为低 (LPR),正常 (NPR) 和高 (HPR) 血小板反应率组.
- 长期随访 (长达8年) 评估主要急性心脏事件 (MACE) 和周围手术性心肌梗塞 (PMI).
主要成果:
- 患有高莱普丁血症的患者表现出明显更高的MACE率 (HR 2.3; P=0.02),即使调整了BMI,高血压和性别.
- 与LPR和NPR组相比,高血小板反应率 (HPR) 组的勒丁水平显著更高 (P=0.047).
- 在高leptinemic患者 (15.1%对6.5%,P=0.22) 中观察到一种趋势,即更高的周围手术心肌梗塞 (PMI) 发生率.
结论:
- 在接受PCI的患者中,升高的勒丁水平与不良的长期心血管结果和高血小板反应性有关.
- 这些发现表明素是PCI患者风险分层的潜在生物标志物.
- 需要进一步的研究来阐明关联勒丁,血小板功能和心血管事件的潜在病理生理机制.
更多相关视频
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
3.4K
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.3K
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
96
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
96
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532
